Hello!
To view this content, please sign up or log in – it’s free and easy! Stay ahead with curated regulatory insights designed for professionals like you.
Brief
On 06 November 2024, the Medicines and Healthcare products Regulatory Agency (MHRA) approved Sparsentan to treat adult patients with primary immunoglobulin A nephropathy (IgAN). This approval follows the International Recognition Procedure (IRP), Route B. The active ingredient in Filspari, Sparsentan, works by blocking receptors for endothelin and angiotensin hormones, thus slowing down kidney damage progression.
Highlights content goes here...
Hello!
To view this content, please sign up or log in – it’s free and easy! Stay ahead with curated regulatory insights designed for professionals like you.
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested
